QQQ   416.36 (-1.67%)
AAPL   165.22 (-1.09%)
MSFT   400.51 (-0.93%)
META   483.43 (-3.66%)
GOOGL   154.21 (-1.15%)
AMZN   174.94 (-2.39%)
TSLA   148.29 (-1.09%)
NVDA   790.23 (-6.67%)
AMD   149.37 (-3.68%)
NIO   3.83 (-4.25%)
BABA   68.94 (+0.09%)
T   16.40 (+0.43%)
F   12.11 (+0.41%)
MU   107.36 (-4.08%)
GE   148.94 (-2.62%)
CGC   8.12 (+3.70%)
DIS   112.20 (-0.20%)
AMC   3.22 (+10.27%)
PFE   25.83 (+1.73%)
PYPL   62.07 (-0.05%)
XOM   119.74 (+1.03%)
QQQ   416.36 (-1.67%)
AAPL   165.22 (-1.09%)
MSFT   400.51 (-0.93%)
META   483.43 (-3.66%)
GOOGL   154.21 (-1.15%)
AMZN   174.94 (-2.39%)
TSLA   148.29 (-1.09%)
NVDA   790.23 (-6.67%)
AMD   149.37 (-3.68%)
NIO   3.83 (-4.25%)
BABA   68.94 (+0.09%)
T   16.40 (+0.43%)
F   12.11 (+0.41%)
MU   107.36 (-4.08%)
GE   148.94 (-2.62%)
CGC   8.12 (+3.70%)
DIS   112.20 (-0.20%)
AMC   3.22 (+10.27%)
PFE   25.83 (+1.73%)
PYPL   62.07 (-0.05%)
XOM   119.74 (+1.03%)
QQQ   416.36 (-1.67%)
AAPL   165.22 (-1.09%)
MSFT   400.51 (-0.93%)
META   483.43 (-3.66%)
GOOGL   154.21 (-1.15%)
AMZN   174.94 (-2.39%)
TSLA   148.29 (-1.09%)
NVDA   790.23 (-6.67%)
AMD   149.37 (-3.68%)
NIO   3.83 (-4.25%)
BABA   68.94 (+0.09%)
T   16.40 (+0.43%)
F   12.11 (+0.41%)
MU   107.36 (-4.08%)
GE   148.94 (-2.62%)
CGC   8.12 (+3.70%)
DIS   112.20 (-0.20%)
AMC   3.22 (+10.27%)
PFE   25.83 (+1.73%)
PYPL   62.07 (-0.05%)
XOM   119.74 (+1.03%)
QQQ   416.36 (-1.67%)
AAPL   165.22 (-1.09%)
MSFT   400.51 (-0.93%)
META   483.43 (-3.66%)
GOOGL   154.21 (-1.15%)
AMZN   174.94 (-2.39%)
TSLA   148.29 (-1.09%)
NVDA   790.23 (-6.67%)
AMD   149.37 (-3.68%)
NIO   3.83 (-4.25%)
BABA   68.94 (+0.09%)
T   16.40 (+0.43%)
F   12.11 (+0.41%)
MU   107.36 (-4.08%)
GE   148.94 (-2.62%)
CGC   8.12 (+3.70%)
DIS   112.20 (-0.20%)
AMC   3.22 (+10.27%)
PFE   25.83 (+1.73%)
PYPL   62.07 (-0.05%)
XOM   119.74 (+1.03%)
Free Trial
OTCMKTS:MYLGF

Mirati Therapeutics (MYLGF) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)
Free MYLGF Stock Alerts
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
355 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis

About Mirati Therapeutics

MethylGene, Inc. operates as a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics for cancer and infectious disease.

MYLGF Stock News Headlines

February 14, 2022 | gurufocus.com
Sectoral Asset Management Inc Buys Mirati Therapeutics Inc, Privia Health Group Inc, Certara ...
January 20, 2022 | gurufocus.com
Should Investors Worry About Mirati Therapeutics Inc's Insider Sells?
April 19, 2024 | Behind the Markets (Ad)
AI healthcare stock poised for 36,996% growth?
Buy Alert Issued For AI Small Cap Our last two AI stocks jumped 150% and 130%... But we just issued a brand new "buy alert" for a new one...
November 12, 2021 | gurufocus.com
International Biotechnology Trust Plc Buys Horizon Therapeutics PLC, Mirati Therapeutics Inc, ...
September 4, 2021 | gurufocus.com
Advisors' Inner Circle Fund III Buys Squarespace Inc, Mirati Therapeutics Inc, Macerich Co, ...
See More Headlines
Receive MYLGF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirati Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
OTCMKTS:MYLGF
CUSIP
N/A
CIK
N/A
Web
N/A
Phone
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
The Next 7 Blockbuster Stocks for Growth Investors Cover
The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Martin Godbout Ph.D (Age 57)
    Chairman of the Board
  • Charles M. Baum M.D. (Age 55)
    Ph.D., President, Chief Executive Officer, Director
  • Mark J. Gergen (Age 51)
    Chief Operations Officer, Executive Vice President
  • Rachel W. Humphrey M.D. (Age 51)
    Chief Medical Officer, Executive Vice President
  • Jamie A. Donadio (Age 38)
    Vice President - Finance
  • Henry J. Fuchs M.D. (Age 55)
    Ph.D., Independent Director
  • Rodney W. Lappe Ph.D. (Age 58)
    Independent Director
  • Peter A. Thompson M.D. (Age 53)
    Independent Director

MYLGF Stock Analysis - Frequently Asked Questions

How do I buy shares of Mirati Therapeutics?

Shares of MYLGF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:MYLGF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
1970’s computer coder issues shocking A.I. warning
TradeSmith
SHOCKING Crypto Leak…
Crypto 101 Media